Korea REGEN Co., Ltd., a holding subsidiary of Aimeike (300896.SZ), terminated Datou's exclusive distribution rights

Zhitongcaijing · 07/21/2025 14:25

Zhitong Finance App News, Aimeike (300896.SZ) announced that the company's holding subsidiary REGEN Biotech, Inc. (hereinafter referred to as “Korea REGEN Company”) delivered a “Cancellation Letter” to Datou Medical Devices (Shanghai) Co., Ltd. (hereinafter referred to as “Datou Company”) on July 18, 2025, to cancel the exclusive distribution agreement and withdraw all relevant authorizations of Datou as the exclusive distributor of AestheFill products in mainland China.

The cancellation of Datou's exclusive distribution rights this time will help maintain sales of Korea's Regen AestheFill products in mainland China and safeguard the interests of listed companies and shareholders. After the cancellation of Datou's exclusive distribution rights, it will not affect the subsequent authorization of South Korea's REGEN Company to sell AestheFill products in mainland China, nor will it affect the operation and sales of aestheFill products. It is not ruled out that the relevant parties will subsequently initiate dispute resolution procedures regarding the cancellation of the exclusive distribution rights. The company will strictly comply with the regulations in accordance with the progress of related matters.